Table 3. Median VE and 95% credible intervals for infection protection in contacts and transmission reduction in cases, by variant, vaccine product, and number of doses.

VE, vaccine effectiveness; BNT162b2, Pfizer-BioNTech mRNA vaccine; ChAdOx1, Oxford AstraZeneca adenovirus vector vaccine.

Variant	Vaccine	Doses	VE infection	VE transmission
Alpha	ChAdOx1	1	-1% (-42%, 36%)	-9% (-63%, 28%)
		2	24% (-41%, 72%)	36% (-29%, 74%)
	BNT162b2	1	51% (4%, 83%)	23% (-18%, 54%)
		2	69% (9%, 95%)	57% (2%, 85%)
Delta	ChAdOx1	1	-1% (-28%, 28%)	15% (-17%, 58%)
		2	9% (-15%, 42%)	49% (18%, 73%)
	BNT162b2	1	0% (-33%, 39%)	10% (-20%, 54%)
		2	18% (-11%, 59%)	36% (-1%, 66%)